Yu Shyr

microscope

IOM study calls for better evidence for biomarker tests

Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine.

Moses, Shyr named to Institute of Medicine cancer therapies panel

Two Vanderbilt-Ingram Cancer Center (VICC) leaders have been named to a panel of the Institute of Medicine (IOM) to help shape national policies on the use of biomarkers for targeted cancer therapies.

Genomic research gains ad-“vantage” with new resources

Vanderbilt University Medical Center has stepped up its support of research aimed at cracking the mysteries of the genome, the master DNA code.

1 2